These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 20483050)
1. Evaluation of disease activity assessments in patients with rheumatoid arthritis and an inadequate response to anti-TNF therapy: analyses of abatacept clinical trial data. Dougados M; Wells G; Schmidely N; Le Bars M; van Riel P; Aletaha D; Schiff M; Smolen J Clin Exp Rheumatol; 2010; 28(2):258-60. PubMed ID: 20483050 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of different methods used to assess disease activity in rheumatoid arthritis: analyses of abatacept clinical trial data. Dougados M; Schmidely N; Le Bars M; Lafosse C; Schiff M; Smolen JS; Aletaha D; van Riel P; Wells G Ann Rheum Dis; 2009 Apr; 68(4):484-9. PubMed ID: 19074177 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Genovese MC; Schiff M; Luggen M; Becker JC; Aranda R; Teng J; Li T; Schmidely N; Le Bars M; Dougados M Ann Rheum Dis; 2008 Apr; 67(4):547-54. PubMed ID: 17921185 [TBL] [Abstract][Full Text] [Related]
4. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. Genovese MC; Becker JC; Schiff M; Luggen M; Sherrer Y; Kremer J; Birbara C; Box J; Natarajan K; Nuamah I; Li T; Aranda R; Hagerty DT; Dougados M N Engl J Med; 2005 Sep; 353(11):1114-23. PubMed ID: 16162882 [TBL] [Abstract][Full Text] [Related]
5. Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy. Genovese MC; Schiff M; Luggen M; Le Bars M; Aranda R; Elegbe A; Dougados M J Rheumatol; 2012 Aug; 39(8):1546-54. PubMed ID: 22798265 [TBL] [Abstract][Full Text] [Related]
6. Assessing the cost-effectiveness of biologic agents for the management of moderate-to-severe rheumatoid arthritis in anti-TNF inadequate responders in Italy: a modelling approach. Cimmino MA; Leardini G; Salaffi F; Intorcia M; Bellatreccia A; Dupont D; Beresniak A Clin Exp Rheumatol; 2011; 29(4):633-41. PubMed ID: 21813056 [TBL] [Abstract][Full Text] [Related]
7. An index of only patient-reported outcome measures, routine assessment of patient index data 3 (RAPID3), in two abatacept clinical trials: similar results to disease activity score (DAS28) and other RAPID indices that include physician-reported measures. Pincus T; Bergman MJ; Yazici Y; Hines P; Raghupathi K; Maclean R Rheumatology (Oxford); 2008 Mar; 47(3):345-9. PubMed ID: 18238788 [TBL] [Abstract][Full Text] [Related]
8. Investigation into the impact of abatacept on sleep quality in patients with rheumatoid arthritis, and the validity of the MOS-Sleep questionnaire Sleep Disturbance Scale. Wells G; Li T; Tugwell P Ann Rheum Dis; 2010 Oct; 69(10):1768-73. PubMed ID: 20610444 [TBL] [Abstract][Full Text] [Related]
9. Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression. Wells AF; Westhovens R; Reed DM; Fanti L; Becker JC; Covucci A; Keystone EC J Rheumatol; 2011 Nov; 38(11):2362-8. PubMed ID: 21885491 [TBL] [Abstract][Full Text] [Related]
10. Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes. Bathon J; Robles M; Ximenes AC; Nayiager S; Wollenhaupt J; Durez P; Gomez-Reino J; Grassi W; Haraoui B; Shergy W; Park SH; Genant H; Peterfy C; Becker JC; Covucci A; Moniz Reed D; Helfrick R; Westhovens R Ann Rheum Dis; 2011 Nov; 70(11):1949-56. PubMed ID: 21821865 [TBL] [Abstract][Full Text] [Related]
11. Greater remission rates in patients with early versus long-standing disease in biologic-naive rheumatoid arthritis patients treated with abatacept: a post hoc analysis of randomized clinical trial data. Yazici Y; Moniz Reed D; Klem C; Rosenblatt L; Wu G; Kremer JM Clin Exp Rheumatol; 2011; 29(3):494-9. PubMed ID: 21722499 [TBL] [Abstract][Full Text] [Related]
12. Proposed severity and response criteria for Routine Assessment of Patient Index Data (RAPID3): results for categories of disease activity and response criteria in abatacept clinical trials. Pincus T; Hines P; Bergman MJ; Yazici Y; Rosenblatt LC; MacLean R J Rheumatol; 2011 Dec; 38(12):2565-71. PubMed ID: 22089467 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness simulation model of biologic strategies for treating to target rheumatoid arthritis in Germany. Beresniak A; Baerwald C; Zeidler H; Krüger K; Neubauer AS; Dupont D; Merkesdal S Clin Exp Rheumatol; 2013; 31(3):400-8. PubMed ID: 23464803 [TBL] [Abstract][Full Text] [Related]
14. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Schiff M; Pritchard C; Huffstutter JE; Rodriguez-Valverde V; Durez P; Zhou X; Li T; Bahrt K; Kelly S; Le Bars M; Genovese MC Ann Rheum Dis; 2009 Nov; 68(11):1708-14. PubMed ID: 19074911 [TBL] [Abstract][Full Text] [Related]
15. Abatacept in biologic-naïve patients and TNF inadequate responders: clinical data in focus. Sherrer Y Curr Med Res Opin; 2008 Aug; 24(8):2283-94. PubMed ID: 18590608 [TBL] [Abstract][Full Text] [Related]
16. Is abatacept an effective treatment for patients with RA who do not respond to other anti-TNF treatments? Taylor PC Nat Clin Pract Rheumatol; 2006 Mar; 2(3):128-9. PubMed ID: 16932670 [No Abstract] [Full Text] [Related]
17. Indirect treatment comparison of abatacept with methotrexate versus other biologic agents for active rheumatoid arthritis despite methotrexate therapy in the United kingdom. Guyot P; Taylor PC; Christensen R; Pericleous L; Drost P; Eijgelshoven I; Bergman G; Lebmeier M J Rheumatol; 2012 Jun; 39(6):1198-206. PubMed ID: 22505698 [TBL] [Abstract][Full Text] [Related]
18. Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial. Westhovens R; Cole JC; Li T; Martin M; Maclean R; Lin P; Blaisdell B; Wallenstein GV; Aranda R; Sherrer Y Rheumatology (Oxford); 2006 Oct; 45(10):1238-46. PubMed ID: 16567357 [TBL] [Abstract][Full Text] [Related]
19. Selective costimulation modulation with abatacept: a look at quality-of-life outcomes in patients with rheumatoid arthritis. Shergy WJ Semin Arthritis Rheum; 2009 Jun; 38(6):434-43. PubMed ID: 18538830 [TBL] [Abstract][Full Text] [Related]